Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_assertion type Assertion NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_head.
- NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_assertion description "[Most importantly, the translation of the described results to human primary samples demonstrated that patients with prostate or breast tumors with low levels of KLF2 and high expression of EZH2 had a shorter overall survival.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_provenance.
- NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_assertion evidence source_evidence_literature NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_provenance.
- NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_assertion SIO_000772 21892211 NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_provenance.
- NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_assertion wasDerivedFrom befree-20150227 NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_provenance.
- NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_assertion wasGeneratedBy ECO_0000203 NP389168.RABE-paUpQyZyCSI24sg5JEahzxzubfH2IQHEzXLpj1Lc130_provenance.